Abstract
Introduction
PSP94, also known as microseminoprotein (MSP), an abundant human seminal plasma protein (Lilja & Abrahamsson 1988 , Green et al. 1990 , Liang et al. 1991 , has been purified from human (Wright et al. 1990 , Baijal-Gupta et al. 1996 and porcine (Fernlund et al. 1994) seminal plasma. The protein has been detected in significantly reduced levels in other human tissues (Johansson et al. 1984 , Brar et al. 1988 , Lilja & Abrahamsson 1988 , Ulvsback et al. 1989 , Weiber et al. 1990 , Teni et al. 1992 , Xuan et al. 1995 and in mucous glands and various secretions (Weiber et al. 1990) .
The amino acid (Johansson et al. 1984 , Seidah et al. 1984 , Akiyama et al. 1985 and DNA sequences (Mbikay et al. 1987 , Green et al. 1990 ) for PSP94 show no similarity with other known proteins. The PSP94 gene, however, has been shown to be similar in its upstream region to that of prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) , with respect to the presence of putative transcription regulatory elements for ubiquitous transcription factors, with the consensus sequences (Faisst & Meyer 1992) . The significance of these elements in none of these genes is known.
The investigations concerning the expression of PSP94 gene so far primarily include the prostate from human (Mbikay et al. 1987 , Green et al. 1990 , primate , Nolet et al. 1991 , pig and rat (Fernlund et al. 1994 (Fernlund et al. , 1996 . Although a clear function for PSP94 has not been identified, its reduced expression in prostate cancer suggests it to be a prognostic indicator in prostate carcinoma , Doctor et al. 1986 , Brar et al. 1988 , Hyakutake et al. 1993 , Liu et al. 1993 , Kammer et al. 1993 . It has also been suggested as an apoptosis-based anti-tumor agent for hormone refractory prostate cancer (Garde et al. 1999 ). Recently we have identified a binding protein for PSP94 in prostate cancer cell lines (LNCaP, PC3) and prostate tissues (Yang et al. 1998a) . The regulation of the expression of PSP94 and its binding protein in LNCaP cells has been suggested to be partially regulated by an autocrine pathway (Yang et al. 1998b) .
PSP94 has also been found in comparable concentrations in serum of men and women . However, in female tissues, the presence of this protein has been controversial , Mbikay et al. 1987 , Weiber et al. 1990 and the site of synthesis of this protein has not been identified. It has previously been demonstrated that the immunoreactivity does not necessarily reflect the site of synthesis (Han et al. 1987) . Hence, it was significant to demonstrate the local synthesis of PSP94 in female urogenital system to determine its involvement in regulation of growth and reproduction. We thus aimed here to establish the expression of PSP94 mRNA in various human non-malignant female reproductive tissues, breast and in a number of established endometrial cancer cell lines.
Materials and Methods

Cell lines and cell cultures
All human endometrial epithelial adenocarcinoma cell lines were from the American Type Cell Culture (ATCC) and maintained in the recommended culture mediums. The epithelial cell line used was RL95-2 (ATCC CRL-1671), the (morphologically characterized) epithelial-like cell lines were KLE (ATCC CRL-1622), HEC-1-A (ATCC HTB-112) and AN3 CA (ATCC HTB-111).
Tissue collection
All the tissues were immediately frozen in liquid nitrogen and stored at 80 C for RNA extractions. The in situ hybridizations (ISH) and immunohistochemistry (IHC) studies were done on the archival surgical material routinely submitted for pathological studies and did not require patient consents. The uterine, ovarian and cervical non-malignant specimens were from patients in their pre-menopausal years, undergoing biopsies or surgeries and were procured from the London Health Science Centre, London, ON, Canada. The uterine biopsies or hysterectomies were performed for gynecological reasons such as benign uterine leimyomas, not endometrial in origin. The placental and prostate benign prostatic hyperplasia (BPH) specimens were from the St Joseph's Health Centre, London, ON, Canada. All the samples were the remaining materials from the pathological diagnosis and involved informed patients consents. The normal breast tissues were obtained from the Tumor Tissue Bank (London Regional Cancer Centre, London, ON, Canada), with the consent of the Tumor Bank Steering committee.
Oligonucleotide primers
Human prostate PSP94 cDNA specific primers were derived from the flanking 5 and 3 non-coding regions; PR1 (5 TACTGATAGGCTAGGCTAC 3 ) was complementary to a sequence near the poly-A tail of the sense strand of PSP94 cDNA (Mbikay et al. 1987 , Green et al. 1990 ) and PR2 (5 TGCTTATCACAATGAATGTTC TCCTGGGC 3 ) represents the first 29 nucleotides of PSP94 cDNA sequence (Green et al. 1990 ). The exon III specific probe consisted of the sequences (5 GTCAG TCTGCCACTCCGAG 3 ), complementary to the PSP94 cDNA sequence (158-176) and the exon IV (5 TCCATTCACTGACAGAACAGGTC 3 ) complementary to (326-348) (Mbikay et al. 1987) . The primers specific for -actin were used as the internal controls. All primers were synthesized by Procyon Biopharma Inc. (London, ON, Canada).
RNA isolation
Total RNA was isolated from all the tissues and cell lines (1-5 10 6 cells, 90% confluent) using the TRIzol reagent (Gibco BRL, Burlington, ON, Canada) as per manufacturer's instructions. The integrity of the RNA was checked on ethidium bromide stained 1·5% denaturing gels (data not shown) and quantified spectrophotometrically.
Reverse transcriptase polymerase chain reaction
The reverse transcriptase polymerase chain reaction (RT-PCR) was performed according to Xuan et al. (1995) with slight modifications using thin-walled tubes (BioRad, Mississauga, ON, Canada) and was not quantitative in nature. The first strand cDNA synthesis was conducted with 3 µg RNA and 1 µg PR1 primer with 50 units of reverse transcriptase (Pharmacia, Uppsala, Sweden). The PCR was performed with 100 pmol PR1 and PR2 primers respectively, using 2·5 units Taq polymerase (Pharmacia). The thermocycle program for PCR consisted of 20 cycles with 30 s at 95 C, 30 s at 60 C, 60 s at 72 C and followed by one cycle for 10 min at 72 C. Portions (10 µl) of PCR products were run on 6% PAGE or 1·5% agarose gels and visualized with ethidium bromide staining. Positive controls contained RNA from prostate (BPH) tissues and negative controls did not contain any RNA. One µg RNA from each tissue was used for RT-PCR under similar conditions, with the primers specific for -actin.
The RT-PCR products were cloned using TA cloning Kit from InVitrogen using pCR 2·1 vector, as per manufacturer's instructions (Invitrogen, Carlsbad, CA, USA), using INV F' One Shot cells for transformation. The screening of the recombinant clones was done by partial restriction mapping. Two independent positive clones were fully sequenced from the normal breast tissues and the KLE cell lines at the sequencing facility, Robarts Research Institute, London ON, Canada and Mobix Core Facility, McMaster University, Hamilton, ON, Canada, respectively. The alignment of DNA sequences was performed using the Wisconsin Sequence Analysis package from GCG Inc.
Southern blot analysis
Southern blotting was performed as previously described (Sambrook et al. 1989) , in which DNA was blotted on to a positively charged membrane (Boehringer Mannheim, Laval, Quebec, Canada), using a Trans-Blot SD semi-dry transfer cell (Bio-Rad). Human PSP94 cDNA probe was labeled with the non-radioactive High Prime digoxigenin (DIG) labeling kit. The exon III and IV probes were labeled using the DIG Oligo-nucleotide 3 End Labeling kit (Boehringer Mannheim). All DIG labeling procedures were performed according to the manufacturer's protocol and the hybridization signals were detected on the Hyper film-ECL (Amersham Life Science Inc., Arlington Heights, IL, USA).
Hybridization with DIG-labeled cDNA probe was done overnight at 42 C in high SDS buffer (SDS 7%; formamide, 50%; 5 SSC; 50 mM sodium phosphate, pH 7·0; N-lauroyl-sarcosine, 0·1% (w/v)) and blocking reagent, 2%. CSPD (Boehringer Mannheim) was used as the chemiluminescence substrate. The same blot was stripped and re-probed with DIG-labeled exon IV oligonucleotide probe under similar hybridization conditions at 48 C. The products from the same set of RT-PCR reactions were run on another gel, under similar conditions and were transferred to a Zeta probe membrane (BioRad). The blot was hybridized with 32 P-labeled exon IV probe, labeled by random priming using an oligonucleotide labeling kit (Pharmacia) to specific activity of 1 10 9 c.p.m. and was exposed overnight to Kodak XAR film (Eastman Kodak, New Haven, CT, USA).
In another set of experiments, the RT-PCR products obtained under similar conditions were transferred to a new positively charged membrane. The blot was hybridized with DIG-labeled exon III probe at 48 C, under similar conditions and hybridization signals were detected as described earlier.
Preparation of tissue sections
Serial microtome sections (5 µm thick) were mounted on Superfrost Plus slides (Fisher Scientific, Fairlawn, NJ, USA) and prepared for immunohistochemistry (IHC) and in situ hybridizations (ISH) using the method described by Lazowski et al. (1994) . The slides were baked for 3-4 days at 45 C. Adjacent serial sections were used for IHC using rabbit polyclonal anti PSP94 (Baijal-Gupta et al. 1996) , raised against native PSP94 or PSP57 antiserum against a synthetic 41-mer peptide (Xuan et al. 1995) or for ISH, as described below.
Preparation and labeling of riboprobe
The 35 S UTP-labeled antisense RNA probe was generated from a 483 bp human PSP94 cDNA insert subcloned into Sma I site of the pBluescript vector-KS (Stratagene, La Jolla, CA, USA). The fragments obtained by linearizing this plasmid with restriction enzymes, XbaI and EcoRI, were gel isolated and used for labeling as sense and antisense RNA probes, respectively, using either T3 or T7 promoters as per recommended protocols (RNA Transcription Kit, Promega, Madison, WI, USA). Probes were labeled to an approximate specific activity of 10 9 c.p.m./µg.
ISH ISH was performed as described by Lazowski et al. (1994) with some modifications to the hybridization conditions. Tissue sections were hybridized with the 35 S-UTP labeled antisense RNA probe generated as described above, at a concentration of 10 6 c.p.m./ml in 1 hybridization buffer (deionized formamide, 50%; NaCl, 0·3 M; Tris-HCl, pH 8, 20 mM; EDTA, 1 mM; Denhardt's solution, 1 ; yeast tRNA, 500 µg/ml; denatured ssDNA, 100 µg/ml; SDS, 0·1%; dithiothreitol (DTT), 100 mM; dextran sulphate, 10%) overnight at 68 C. Control sections were hybridized with 35 S-UTP labeled sense RNA probe generated from the same cDNA, as described earlier. The specimens were finally exposed to X-ray film BioMax MR (Eastman Kodak) for 18-24 h. The slides were coated with photoemulsion (NTB-3 nuclear track emulsion, Eastman Kodak) and exposed at 4 C for 2-4 weeks, depending on the autoradiographic intensity of the sections on the X-ray film. The photoemulsion on the sections was developed with D-19 developer (Eastman Kodak), fixed, and the slides were counter-stained with Harris's hematoxylin and eosin for morphologic characterization and mounted with paramount (Fisher Scientific). The distribution and location of the silver grains were examined by microscopy under dark and light field illumination with several magnifications, using Aristoplan Photomicroscope (Leica, Heerbrugg, Switzerland). Two to three sets of slides from each tissue were studied for reproducibility.
The specificity of ISH was demonstrated by lack of specific autoradiographic signals, when the adjacent tissue sections were hybridized with a 35 S labeled sense RNA probe or by abolishment of specific hybridization when the hybridization was performed on adjacent tissue sections that were pretreated with RNAse.
Semiquantitative analysis of ISH data
The PSP94 mRNA signals on the ISH studies with the endometrial, breast and prostate tissue sections were quantified by the Northern Eclipse Imaging system software (Empix Inc., Missisuaga, ON, Canada). The measurements were done in bright field microscopy at 40 magnifications. The density of the grains in the selected regions of the tissues were denoted in pixel units (background counts were taken into account). The area selected for assessment on each specimen remained constant (1 10 4 µm) to eliminate any variability. Prostate (BPH) were considered with highest positive signals in the cytoplasm of the epithelial cells with 5900-8000 pixel counts (=High). Based on the pixel counts in BPH tissues, the signals in other specimens were categorized as medium positive signals with 1000-5000 pixels (=Medium); low positive signals in the perinuclear region with 700-1000 pixels (=Low); negative signals=to the background counts 40-400 pixels.
Results
Southern blot analysis of RT-PCR products
Using RT-PCR reactions with PSP94-specific primers, and prostate (BPH) as a positive control (Brar et al. 1988) , we identified PSP94 mRNA in the biopsy specimens from the endometrium (n=10), myometrium (n=5), ovary (n=5), breast (n=5), placenta (n=3), cervix (n=3) and two different endometrial cancer cell lines on ethidium bromide stained PAGE (data not shown), which included the molecular weight markers (100 bp ladder).
RT-PCR products from the endometrial cell lines, KLE and RL95-2, and from the normal breast tissues were further analyzed by partial restriction mapping. Two clones each from these were sequenced in both directions. The transcripts from the KLE cells and the breast tissues were identical in size (487 bp) to that of the prostate PSP94 fragment. The DNA sequence alignment using the GCG Sequence Analysis Package confirmed 100% identity of the entire coding region of these transcripts to human prostate PSP94, as reported by Mbikay et al. (1987) and Green et al. (1990) . Limited substitutions were seen in the 3 non-coding region of the gene from the KLE cells. The Genbank Accession number assigned to the nucleotide sequence of cDNA cloned from cell line KLE was U78976. None of the sequences obtained from the RL95-2 from a number of batches (n=4) of RL95-2 cells matched with PSP94 cDNA sequence, suggesting these as the artifacts of the PCR amplification.
Southern blot analysis of the RT-PCR amplified products from various samples, as described earlier, with DIG-labeled PSP94 cDNA is shown in Fig. 1A . Signals for two different transcripts were detected in the endometrium (lane 1), myometrium (lane 2) and prostate (lane 5) tissues. The higher band corresponded to PSP94 487 bp (Mbikay et al. 1987 , Green et al. 1990 , denoted with long arrow and lower band 381 bp, denoted with short arrow, corresponding to PSP57, the alternately spliced form of PSP94 (Xuan et al. 1995) . However, no RT-PCR product was detected in one of the myometrial samples tested. The endometrial tissues were from early secretory (n=5), late secretory (n=3), to late proliferative (n=2) phases of the cycling endometrium. Both PSP94 and PSP57 were identified in about equal intensities in all the endometrial samples analyzed independent of phase of the cycle (data not shown). The RT-PCR assays used here were not quantitative and conclusions as to the apparent variations in levels of expression observed between the samples and also the proportions of the two different transcripts could not be made. The KLE (lane 7) and AN3 CA (lane 8) cell lines showed only 487 bp transcript (Fig. 1A) . No signal was detected with HEC-1-A or RL95-2 (data not shown) cell lines or with negative controls without RNA. The integrity of RNA isolated from the samples was confirmed by RT-PCR with primers for human -actin (data not shown).
The same blot as shown in Fig. 1A , when stripped and re-probed with DIG-labeled exon IV probe, shows two bands (PSP94 and PSP57) with the endometrium (lane 1 An identical blot, as described earlier, probed with exon III specific probe (Fig. 1C) to confirm the identity of PSP57 transcript, detected only the larger 487 bp in the prostate (lane 1), endometrium (lane 2) and myometrium (lane 3), suggesting the deletion of the exon III in these tissues similar to prostate (Xuan et al. 1995) . The ovary (lane 4) and KLE cells (lane 5), however, showed same results as with the PSP94 cDNA probe described earlier.
ISH
The samples from the cycling endometrium, early secretory (n=9), late secretory (n=3) and proliferative (n=3) phases, and from the normal breast (n=4) were selected for ISH studies. Prostate (BPH) tissues (n=6) were used as positive controls. The 35 S-labeled antisense riboprobe hybridized to the epithelial cells of the endometrial glands (Fig. 2A) . Bright field microscopy also shows PSP94 mRNA signals specifically in the epithelial cells of endometrium (Fig. 2E ) and in breast (Fig. 2F ) with no signals in the stromal cells of these tissues. The specificity of the probe was demonstrated on the adjacent tissue sections by the lack of specific hybridization of the sense riboprobe to the endometrial tissues (Fig. 2C) , under identical conditions.
Using the same antisense riboprobe as used for the endometrial specimens ( Fig. 2A) , significantly greater hybridization signals were observed in the epithelial cells of prostate glands (Fig. 3A) under identical conditions. No signals were detected in the stromal cells. The adjacent tissue sections hybridized with 35 S-labeled sense riboprobe displayed no specific signals (Fig. 3C) , showing the integrity of the probe. Furthermore, complete abolition of the specific hybridization signals was observed when RNAse pretreatment preceded the hybridization with the antisense RNA probe for all the tissues tested, confirming the specificity of the probe. Table 1 shows the results of the image analysis of the ISH data on various stages of the cycling endometrium and breast tissues. Prostate (BPH) was used as a positive control. The mRNA quantification from the early secretory phase endometrium showed an average of 3620 pixel counts with a standard deviation (..) of 944, denoted as medium expression. Relatively lower counts for PSP94 signal were detected in the late secretory phase and no signals in the proliferative phase of the endometrium. The PSP94 mRNA levels in the normal glands of the breast tissues were also in the medium range.
Evaluation of PSP94 mRNA (ISH) signals
IHC
The early secretory phase of the endometrium showed low but specific immunoreactivity for PSP94 in the cytoplasm of the epithelial cells of these glands and in the luminal lining (Fig. 2B) , with little or no immunoreactivity in the stromal cells. In the prostate, however, the immunoreactivity was significantly higher in the cytoplasm of the epithelial cells and also in the secretions of the glandular lumen (Fig. 3B) . The specificity of the antibody was demonstrated by total abolition of the immunostaining of the endometrial (Fig. 2D ) and the prostate specimens ( Fig. 3D ) with immuno-absorbed PSP94 antiserum. No PSP57 protein was detected by IHC using PSP57-specific antibody, either in the endometrium or in the prostate tissues.
Discussion
In this study we have demonstrated PSP94 transcripts in the human endometrium, myometrium, breast, ovary, placenta and in the endometrial cancer cell lines, KLE and AN3 CA by RT-PCR and Southern blot analysis. Sequencing the RT-PCR products further substantiated these results.
Previous studies on the distribution of this protein in female genital tract include the epithelium of the fallopian tubes, uterine cervix, ovarian follicular secretions (Weiber et al. 1990 , Kammer et al. 1990 . MSP has also been detected in the endometrial and breast tissues by IHC (Teni et al. 1992) , however its site of synthesis in these tissues is not known. To our knowledge, this is the first evidence for the specific localization of PSP94 mRNA and co-localization of the protein in the same glandular epithelial cells of the human endometrium, albeit at a lower abundance than prostate. These data provided a strong indication for a local site of synthesis of the protein (PSP94) in the endometrium.
Although PSP94 mRNA was detected in the early and late secretory as well in the proliferative phases of the cycling endometrium by RT-PCR, the conclusion regarding the apparent variations in the levels of expression between samples could not be made by this procedure. We quantified the ISH hybridization signals employing a novel computerized image analysis system (Petrik et al. 1999) . The use of radioactive probes for ISH analysis facilitated the estimation of the grains in dark or bright field microscopy to provide reliable counts. Significantly higher levels of PSP94 signals were detected in the early secretory phase endometrium as compared with the late secretory phase, with no signals in the proliferative phase of the cycle. The data strongly suggest an association of PSP94 with the cyclic proliferation of the endometrium and its perspective role as a local regulator of uterine function. Among all the tissues tested, only the endometrial and myometrial tissues showed prevalence of the two transcripts, PSP94, and its splice variant PSP57, However, no PSP57 protein could be detected in either of these tissues, as reported earlier for the prostate (Xuan et al. 1995) . The mechanism of its regulation and expression in tissue-/cell-specific manner is not yet determined.
In conclusion, this study indicates significant expression of PSP94 transcript in a number of non-pathological female reproductive tissues and in the endometrial cancer cell lines. Furthermore, PSP94 mRNA was found to be expressed in much higher amounts in the early secretory stage of the cycling endometrium. These data suggest its association with organs highly influenced by the endocrine hormones. Studying the levels of expression of PSP94 gene in the biopsies of the normal female reproductive tissues, from patients under hormonal therapy, and from biopsies from various carcinomas, may further elucidate its significance in normal and tumor biology of the female reproductive system.
